Bilayered osmotic pump type preparation of controlled release tablet of Breviseapini

A technology of osmotic pump controlled release and breviscapine, which is applied in the field of medicine, can solve the problems of wasting drugs, delaying treatment, and failing to reach the therapeutic concentration, etc., and achieves reducing the number of times of taking drugs, good drug release correlation, and lasting balanced blood drug concentration Effect

Inactive Publication Date: 2004-03-10
SHENYANG PHARMA UNIVERSITY
View PDF4 Cites 45 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to pain, fear of trouble, etc., patients will intentionally or unintentionally change the medication plan, and miss one or two doses. The concentr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bilayered osmotic pump type preparation of controlled release tablet of Breviseapini
  • Bilayered osmotic pump type preparation of controlled release tablet of Breviseapini
  • Bilayered osmotic pump type preparation of controlled release tablet of Breviseapini

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Using film coating technology and powder direct compression method, scutellarin is made into double-layer osmotic pump controlled release tablets, and the drug-containing layer is laser drilled to achieve the purpose of controlled release. Present embodiment 1 (composition is calculated by tablet core weight percentage) contains following composition:

[0024] Breviscapine 33.0%

[0025] Polyoxyethylene N80 65.9%

[0026] Magnesium Stearate Appropriate amount

[0027] Boost layer:

[0028] Polyoxyethylene WSR303 70.0%

[0029] Hypromellose 3.6%

[0030] Sodium Chloride 18%

[0031] Povidone 5.8%

[0032] Iron oxide red amount

[0033] Magnesium Stearate Appropriate amount

[0034] Coating layer:

[0035] Composition of semi-permeable membrane coating solution (for every 1000 tablets)

[0036] Cellulose acetate 25g

[0037] Polyethylene glycol (PEG4000) 0.85g

[0038] Acetone: water 805ml

[0039] Hydrophilic polymer polyoxyethylene N80 is the skeleton mater...

Embodiment 2

[0041] Same as in Example 1, adopt film coating technology, wet granulation and tabletting to make scutellarin into double-layer osmotic pump controlled-release tablets. Present embodiment 2 (composition is calculated by tablet core weight percentage) contains following composition:

[0042] Drug layer:

[0043] Breviscapine 32.3%

[0044] Polyoxyethylene N10 64.5%

[0045] Magnesium Stearate Appropriate amount

[0046] 5% povidone K30 ethanol solution appropriate amount

[0047] Boost layer:

[0048]Polyoxyethylene WSR301 67.1%

[0049] Hypromellose 3.6%

[0050] Sodium chloride 17.9%

[0051] Povidone 5.8%

[0052] Iron oxide red amount

[0053] Magnesium Stearate Appropriate amount

[0054] 8% povidone K30 ethanol solution appropriate amount

[0055] Coating layer:

[0056] Composition of semi-permeable membrane coating solution (for every 1000 tablets)

[0057] Cellulose acetate 25g

[0058] Polyethylene glycol (PEG4000) 0.85g

[0059] Acetone: water 805ml ...

Embodiment 3

[0062] Adopt film coating technology with example 1. Present embodiment 3 (composition is calculated by tablet core weight percentage) contains following composition:

[0063] Drug layer:

[0064] Breviscapine 14.2%

[0065] Hypromellose 31.7%

[0066] Poloxamer 10.7%

[0067] Magnesium Stearate Appropriate amount

[0068] 10% povidone K30 ethanol solution appropriate amount

[0069] Boost layer:

[0070] Polyoxyethylene WSR303 24.5%

[0071] Hypromellose 1.2%

[0072] Sodium Chloride 3.6%

[0073] Povidone 10.7%

[0074] Iron oxide red amount

[0075] Magnesium Stearate Appropriate amount

[0076] 10% povidone K30 ethanol solution appropriate amount

[0077] Coating layer:

[0078] Composition of semi-permeable membrane coating solution (for every 1000 tablets)

[0079] Cellulose acetate 25g

[0080] Polyethylene glycol (PEG4000) 0.85g

[0081] Acetone: water 805ml

[0082] The hydrophilic polymer hypromellose is used as the skeleton material; poloxamer is us...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Apertureaaaaaaaaaa
Login to view more

Abstract

A dual-layer release-controllable osmotic breviscapine tablet for treating cerebral thrombosis, coronary heart disease and cardiovascular disease is prepared from breviscapine, release-controlling additive for medicine layer, and release-controlling additive for auxiliary layer. Its advantages are high and durable curative effect and low toxic by-effect.

Description

Technical field: [0001] The invention relates to the technical field of medicine, in particular to a scutellarin double-layer osmotic pump controlled-release tablet preparation for treating cardiovascular and cerebrovascular diseases administered once a day. Background technique: [0002] Breviscapine has better effects on improving cardiovascular and cerebrovascular blood flow, anti-platelet aggregation, and anti-oxidative free radicals. Clinically, it is mostly used to treat cerebral thrombosis, angina pectoris of coronary heart disease, myocardial ischemia injury, etc. It is a good medicine for treating cardiovascular and cerebrovascular diseases. It is a flavonoid substance extracted from Erigeron breviscapus, almost insoluble in water, soluble in alkali and glacial acetic acid, slightly soluble in organic solvents. The equilibrium solubility (37°C) in artificial gastric juice and water pH6.8 phosphate buffer is 0.001, 0.03, 8 (mg / ml). The oil / water partition coefficie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/22A61K31/7048A61P9/10
Inventor 潘卫三何燕
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap